Ultragenyx Pharmaceutical Inc.
$25.06
▲
4.81%
2026-04-21 09:03:02
www.ultragenyx.com
NMS: RARE
Explore Ultragenyx Pharmaceutical Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$2.39 B
Current Price
$25.06
52W High / Low
$42.37 / $18.29
Stock P/E
—
Book Value
$-0.83
Dividend Yield
—
ROCE
-46.6%
ROE
-6.08%
Face Value
—
EPS
$-5.83
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
1,371
Beta
0.25
Debt / Equity
-0.45
Current Ratio
2.48
Quick Ratio
2.34
Forward P/E
287.97
Price / Sales
3.4
Enterprise Value
$2.83 B
EV / EBITDA
-5.65
EV / Revenue
4.2
Rating
Strong Buy
Target Price
$52.45
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
- Valuation is rich on a P/E basis.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Corvus Pharmaceuticals, Inc. | $15.54 | — | $1.31 B | — | -69.6% | -32.6% | $26.95 / $3.11 | $0.82 |
| 2. | Relay Therapeutics, Inc. | $16.4 | — | $3 B | — | -50.82% | -41.12% | $17.32 / $2.53 | $3.26 |
| 3. | X4 Pharmaceuticals, Inc. | $4.19 | — | $372.04 M | — | -32.82% | -75.99% | $6.63 / $1.35 | $2.05 |
| 4. | NovaBay Pharmaceuticals Inc | $1.4 | — | $51.92 M | 0% | -96.1% | 190.01% | $99.75 / $1.11 | $-0.92 |
| 5. | Fortrea Holdings Inc. | $10.44 | — | $976.14 M | — | -1.7% | -1.02% | $18.67 / $3.97 | $6.05 |
| 6. | MediWound Ltd. | $17.35 | — | $226.34 M | — | -41.75% | -63.86% | $22.5 / $14.9 | $3.4 |
| 7. | REGENXBIO Inc. | $9.47 | — | $488.82 M | — | -48.13% | -1.07% | $16.19 / $5.85 | $2.02 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 207.28 M | 159.93 M | 166.5 M | 139.29 M | 164.88 M | — |
| Operating Profit | -113.28 M | -170.89 M | -107.89 M | -142.94 M | -122.28 M | — |
| Net Profit | -128.56 M | -180.41 M | -114.95 M | -151.08 M | -133.38 M | — |
| EPS in Rs | -1.31 | -1.84 | -1.17 | -1.54 | -1.36 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 673 M | 560 M | 434 M | 363.33 M |
| Operating Profit | -535 M | -536 M | -569 M | -648.92 M |
| Net Profit | -575 M | -569 M | -607 M | -707.42 M |
| EPS in Rs | -5.85 | -5.79 | -6.17 | -7.2 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 1.53 B | 1.5 B | 1.49 B | 1.55 B |
| Total Liabilities | 1.6 B | 1.24 B | 1.22 B | 1.19 B |
| Equity | -80 M | 255 M | 275.41 M | 352.49 M |
| Current Assets | 951 M | 817 M | 732.18 M | 883.9 M |
| Current Liabilities | 384 M | 344 M | 280.44 M | 261.21 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -466 M | -414 M | -475 M | -380.46 M |
| Investing CF | 236 M | -18 M | 168 M | -291.65 M |
| Financing CF | 478 M | 399 M | 388 M | 501.21 M |
| Free CF | -487 M | -434 M | -522 M | -526.59 M |
| Capex | -21 M | -20 M | -47 M | -146.12 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 29.03% | 19.45% | — | — |
| Earnings Growth % | 6.26% | 14.2% | — | — |
| Profit Margin % | -101.61% | -139.86% | -194.71% | — |
| Operating Margin % | -95.71% | -131.11% | -178.6% | — |
| Gross Margin % | 86.25% | 89.63% | 92.21% | — |
| EBITDA Margin % | -83.57% | -119.12% | -176.28% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.